Navigation Links
A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market

Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical

Gold Standard Drug by 2011, According to a New Report from Decision


WALTHAM, Mass., July 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a weight neutral oral antidiabetic drug would earn a 25 percent patient share in the treatment of type 2 diabetes, according to surveyed primary care physicians. Given the prices set for each of the drug profiles and the size of the type 2 diabetic patient population in 2011, a 25 percent patient share would result in sales of $4.1 billion for an agent fitting the report's Minimal Acceptable drug profile and $8.1 billion for an agent fitting the report's Major Achievement profile.

The new report entitled Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia also finds that Novo Nordisk's liraglutide will become the new Decision Resources' proprietary clinical gold standard for the treatment of type 2 diabetes by 2011 as surveyed primary care physicians indicate that liraglutide has competitive advantages in terms of efficacy and safety in comparison to the current gold standard, metformin. Although liraglutide has disadvantages in the area of delivery because of its subcutaneous injectable formulation, its positive efficacy and safety attributes offset its disadvantage in delivery.

"Interviewed primary care physicians also state that liraglutide offers a considerable advantage over other current and emerging type 2 diabetes therapies in terms of weight loss," said Donny Wong, Ph.D., principal analyst at Decision Resources. "As a result, we forecast liraglutide to become the clinical gold standard among the agents covered in our analysis."

About the Report

Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. High Birth Weight Doubles Risk of Rheumatoid Arthritis
2. Weight Watchers Receives Adverse U.K. VAT Ruling
3. Heavy birthweight increases risk of developing rheumatoid arthritis
4. Heavy birthweight babies twice as likely to develop rheumatoid arthritis
5. One Year Later, Millions are Losing Weight with alli(R)
6. Weight gain within the normal range increases risk of chronic kidney disease
7. Big, Well-Balanced Breakfast Aids Weight Loss
8. Minimally-invasive weight loss surgery improves health and morbidly obese teens
9. Weight Loss After Gastric Bypass Is Key to Easing Diabetes
10. A Simple Weight Loss Diet: Scientific, Safe and Basically Free
11. Weight loss after gastric bypass surgery may protect against infection and cancer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... ... 24, 2015 , ... Aided by seed funding from the Ron Foley Foundation, ... yield insights into how to detect and treat pancreatic cancer (PC). , WCHN ... non-coding RNA molecules (ncRNA), genetic material that is present in the blood of patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Innovative Blending, a household invention that revolutionizes the vending ... Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... 24, 2015 --> ... MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects there. ,  ,Our 199-page report ... lucrative areas in the industry and the future market ...
(Date:11/24/2015)... Inc., an industry leader in LCD screen protection and glare-elimination technology, is providing a vital solution ... patient monitoring or electronic documentation system. Photo - ... ... ... A study in 2013 by the National Institutes of ...
Breaking Medicine Technology: